Aclaris Therapeutics
ACRS
34 hedge funds and large institutions have $277M invested in Aclaris Therapeutics in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 5 closing their positions.
5,055% more capital inflows, than outflows
Capital inflows: $83.8M | Capital outflows: $1.63M
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
21.42% more ownership
Funds ownership: 51.04% → 72.46% (+21%)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 33 → 34 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$1.21M |
| 2 |
Turner Investments
Berwyn,
Pennsylvania
|
+$560K |
| 3 |
State Street
Boston,
Massachusetts
|
+$538K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$369K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$344K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Spark Investment Management
New York
|
-$1.04M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$295K |
| 3 |
BlackRock Fund Advisors
San Francisco,
California
|
-$157K |
| 4 |
EEG
E.E. Geduld
|
-$42.6K |
| 5 |
Barclays
London,
United Kingdom
|
-$26K |
ACRS Hedge Fund Activity: Q1 2016 in Review
34 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2016, worth a combined $277M — down 0.15% from $277M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ACRS positions and 5 closed out — a net gain of 1 holder — while 16 added to existing stakes and 6 trimmed.
The largest buyer was RA Capital Management, adding an estimated $1.21M. The largest seller was Spark Investment Management, exiting entirely with an estimated $1.04M sold.
- 34 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2016, up from 33 in Q4 2015.
- Funds reported $277M of Aclaris Therapeutics stock for Q1 2016, down 0.15% quarter-over-quarter.
- 6 funds opened new Aclaris Therapeutics positions in Q1 2016 and 5 closed out, a net change of +1 holder.
- The largest Aclaris Therapeutics buyer in Q1 2016 was RA Capital Management, an estimated $1.21M added.
- The largest Aclaris Therapeutics seller in Q1 2016 was Spark Investment Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q1 2016.